Pharming Group N.V. Logo

Pharming Group N.V.

Develops & commercializes protein & precision medicines for rare, life-threatening diseases.

PHARM | AS

Overview

Corporate Details

ISIN(s):
NL0010391025 (+1 more)
LEI:
724500DCJ9MPG74JEH91
Country:
Netherlands
Address:
Darwinweg 24, 2333CR Leiden
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients with rare, debilitating, and life-threatening diseases. The company's portfolio focuses on protein replacement therapies and precision medicines designed to address significant unmet medical needs. By concentrating on both development and commercialization, Pharming aims to provide transformative therapies to underserved patient populations worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:23
Earnings Release
Pharming Group reports second quarter and first half 2025 financial results and…
Dutch 669.6 KB
2025-07-31 08:23
Earnings Release
Pharming Group reports second quarter and first half 2025 financial results and…
English 589.3 KB
2025-07-31 07:16
Earnings Release
Pharming Group N.V., Halfjaarlijkse financiële verslaggeving
English 589.3 KB
2025-06-24 07:35
Regulatory News Service
Pharming Group to host webcast on findings of a new study published in Cell adv…
Dutch 290.6 KB
2025-06-24 07:35
Regulatory News Service
Pharming Group to host webcast on findings of a new study published in Cell adv…
English 260.5 KB
2025-06-12 07:44
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
Dutch 182.9 KB
2025-06-12 07:44
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
English 176.9 KB
2025-05-01 06:28
Pre-Annual General Meeting Information
Pharming Group announces the 2025 Annual General Meeting of Shareholders and th…
English 182.9 KB
2025-04-23 09:44
Environmental & Social Information
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as…
English 296.9 KB
2025-04-03 07:26
Annual Report (ESEF)
Pharming Group N.V., Jaarlijkse financiële verslaggeving
English 25.3 MB
2025-03-04 15:29
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
Dutch 224.7 KB
2025-03-04 15:29
Board/Management Information
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
English 224.4 KB
2025-02-21 07:38
M&A Activity
Pharming Technologies B.V. vergroot haar belang in Abliva AB (publ) naar 92,70 …
Dutch 254.4 KB
2025-02-21 07:38
M&A Activity
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70…
English 284.0 KB
2025-02-10 07:36
M&A Activity
Pharming Technologies B.V. declares unconditional and completes the recommended…
Dutch 272.1 KB

Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-24 D.A. Jorn Non-Executive member Other 7,446 N/A
2023-03-21 P. Sekhri Non-Executive member Other 9,363 N/A
2022-10-27 P. Sekhri Non-Executive member Buy 13,013 12,232.22 EUR
2022-10-27 M. Pykett Non-Executive member Buy 9,760 9,174.40 EUR
2022-08-04 P. Sekhri Non-Executive member Buy 13,013 10,000.23 EUR
2022-08-04 S. Baert Non-Executive member Buy 9,760 7,500.36 EUR
2022-05-25 J. van der Meijs Non-Executive member Buy 9,300 86,490,000.00 EUR
2022-05-25 P. Sekhri Non-Executive member Buy 12,398 9,527.62 EUR
2022-05-25 M. Pykett Non-Executive member Buy 9,300 7,146.86 EUR
2022-03-24 S. de Vries Non-Executive member Buy 318,150 232,249.50 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.